These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 33034421)

  • 1. An open-label, randomized crossover study to evaluate the acceptability and preference for contraceptive options in female adolescents, 15 to 19 years of age in Cape Town, as a proxy for HIV prevention methods (UChoose).
    Gill K; Happel AU; Pidwell T; Mendelsohn A; Duyver M; Johnson L; Meyer L; Slack C; Strode A; Mendel E; Fynn L; Wallace M; Spiegel H; Jaspan H; Passmore JA; Hosek S; Smit D; Rinehart A; Bekker LG
    J Int AIDS Soc; 2020 Oct; 23(10):e25626. PubMed ID: 33034421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. "It's already in your body and it's preventing": a qualitative study of African female adolescent's acceptability and preferences for proxy HIV prevention methods in Cape Town, South Africa.
    Fynn L; Gill K; Wallace M; Atujuna M; Duyver M; Ngcobo P; Spiegel H; Rinehart A; Hosek S; Bekker LG
    BMC Public Health; 2023 Nov; 23(1):2143. PubMed ID: 37919697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of the contraceptive vaginal ring (NuvaRing) compared with a combined oral contraceptive in Chinese women: a 1-year randomised trial.
    Fan GS; Ren M; Di W; Su P; Chang Q; Wu S; Qin Y; Korver T; Marintcheva-Petrova M; Yacik C; McCrary Sisk C; Wang G
    Eur J Contracept Reprod Health Care; 2016 Aug; 21(4):303-9. PubMed ID: 27339759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 microg of ethinyl estradiol and 3 mg of drospirenone.
    Ahrendt HJ; Nisand I; Bastianelli C; Gómez MA; Gemzell-Danielsson K; Urdl W; Karskov B; Oeyen L; Bitzer J; Page G; Milsom I
    Contraception; 2006 Dec; 74(6):451-7. PubMed ID: 17157101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hormonal contraception alters vaginal microbiota and cytokines in South African adolescents in a randomized trial.
    Balle C; Konstantinus IN; Jaumdally SZ; Havyarimana E; Lennard K; Esra R; Barnabas SL; Happel AU; Moodie Z; Gill K; Pidwell T; Karaoz U; Brodie E; Maseko V; Gamieldien H; Bosinger SE; Myer L; Bekker LG; Passmore JS; Jaspan HB
    Nat Commun; 2020 Nov; 11(1):5578. PubMed ID: 33149114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined contraceptive ring versus combined oral contraceptive (30-μg ethinylestradiol and 3-mg drospirenone).
    Mohamed AM; El-Sherbiny WS; Mostafa WA
    Int J Gynaecol Obstet; 2011 Aug; 114(2):145-8. PubMed ID: 21669426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of a contraceptive vaginal ring (NuvaRing) compared with a combined oral contraceptive: a 1-year randomized trial.
    Oddsson K; Leifels-Fischer B; de Melo NR; Wiel-Masson D; Benedetto C; Verhoeven CH; Dieben TO
    Contraception; 2005 Mar; 71(3):176-82. PubMed ID: 15722066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of the novel combined contraceptive vaginal ring NuvaRing for ovulation inhibition.
    Mulders TM; Dieben TO
    Fertil Steril; 2001 May; 75(5):865-70. PubMed ID: 11334895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The contraceptive vaginal ring, NuvaRing(®), a decade after its introduction.
    Roumen FJ; Mishell DR
    Eur J Contracept Reprod Health Care; 2012 Dec; 17(6):415-27. PubMed ID: 23113828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects on cycle control and bodyweight of the combined contraceptive ring, NuvaRing, versus an oral contraceptive containing 30 microg ethinyl estradiol and 3 mg drospirenone.
    Milsom I; Lete I; Bjertnaes A; Rokstad K; Lindh I; Gruber CJ; Birkhäuser MH; Aubeny E; Knudsen T; Bastianelli C
    Hum Reprod; 2006 Sep; 21(9):2304-11. PubMed ID: 16763008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized trial of the effect of tailored versus standard use of the combined oral contraceptive pill on continuation rates at 1 year.
    Stephenson J; Shawe J; Panicker S; Brima N; Copas A; Sauer U; Wilkinson C; Akintomide H; O'Brien P
    Contraception; 2013 Oct; 88(4):523-31. PubMed ID: 23663917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring.
    Timmer CJ; Mulders TM
    Clin Pharmacokinet; 2000 Sep; 39(3):233-42. PubMed ID: 11020137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The combined contraceptive vaginal ring (NuvaRing) and lipid metabolism: a comparative study.
    Tuppurainen M; Klimscheffskij R; Venhola M; Dieben TO
    Contraception; 2004 May; 69(5):389-94. PubMed ID: 15105061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Residual hormone levels in used contraceptive rings as a measurement of adherence to vaginal ring use.
    Haaland RE; Holder A; Evans-Strickfaden T; Nyagol B; Makanga M; Oyaro B; Humwa F; Williams T; McLellan-Lemal E; Desai M; Huey MJ
    Contraception; 2017 Jun; 95(6):602-604. PubMed ID: 28372978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative study on the efficacy and acceptability of two contraceptive pills administered by the vaginal route: an international multicenter clinical trial.
    Coutinho EM; de Souza JC; da Silva AR; de Acosta OM; Alvarez F; Brache V; Garza Flores J; Vasquez-Estrada L; Santo R; Bassol S
    Clin Pharmacol Ther; 1993 Jan; 53(1):65-75. PubMed ID: 8422744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High acceptability and satisfaction with NuvaRing use.
    Szarewski A
    Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 2():31-6; discussion 37-9. PubMed ID: 12659400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of uterine concentrations of ethinyl estradiol and etonogestrel after use of a contraceptive vaginal ring and an oral contraceptive.
    Roumen FJ; Dieben TO
    Fertil Steril; 2006 Jan; 85(1):57-62. PubMed ID: 16412731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-acting reversible contraceptive acceptability and unintended pregnancy among women presenting for short-acting methods: a randomized patient preference trial.
    Hubacher D; Spector H; Monteith C; Chen PL; Hart C
    Am J Obstet Gynecol; 2017 Feb; 216(2):101-109. PubMed ID: 27662799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomised trial of a contraceptive vaginal ring in women at risk of HIV infection in Rwanda: Safety of intermittent and continuous use.
    Kestelyn E; Agaba S; Van Nuil JI; Uwineza M; Umulisa MM; Mwambarangwe L; Ndagijimana JC; De Baetselier I; Buyze J; Delvaux T; Crucitti T; Jespers V; van de Wijgert JHHM;
    PLoS One; 2018; 13(6):e0197572. PubMed ID: 29856848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of the NuvaRing® Applicator in healthy females: a multicenter, open-label, randomized, 2-period crossover study.
    Feldman R; Frenkl TL; Yacik C; Wang Y; Fox MC
    Contraception; 2016 Oct; 94(4):362-5. PubMed ID: 27207028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.